RABL3

Across TCGA pan-cancer cohorts, RABL3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RABL3 data layer compared with 18 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RABL3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RABL3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where RABL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.887	0.198	.024	9	view →
PDAC	DFS	Quartile	All	0.659	0.315	.008	7	view →
LUAD	OS	Tertile	II,III,IV	0.866	0.306	.004	6	view →
HNSC	DFS	Quartile	III,IV	0.931	0.694	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RABL3–CCRCC (DFS)

Open the CCRCC breakdown →